Table 4.
Demographics and RBP1 methylation status* of grade II–IV glioma samples (n = 198)
| Demographic | Total cohort † by targeted bisulfite sequencing | GBM survival cohort within the total cohort | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Methylated | Unmethylated | Total | Methylated | Unmethylated | |||||||
| No. of patients | 198 | 79 | 119 | 124 | 22 | 102 | ||||||
| Mean age at diagnosis, y (range) | 48.5 (19–79) | 39.5 (19–75) | 54.4 (21–79) | 53.0 (24–79) | 43.7 (24–75) | 55.0 (31–79) | ||||||
| Sex | ||||||||||||
| No. of males | 122 | 51 | 71 | 70 | 14 | 56 | ||||||
| No. of female | 76 | 28 | 48 | 54 | 8 | 46 | ||||||
| Tissue pathology, no. of patients | ||||||||||||
| Astrocytoma grade II | 9 | 7 | 2 | 0 | 0 | 0 | ||||||
| Oligodendroglioma grade II | 16 | 16 | 0 | 0 | 0 | 0 | ||||||
| Oligoastrocytoma grade II | 4 | 4 | 0 | 0 | 0 | 0 | ||||||
| Astrocytoma grade III | 13 | 7 | 6 | 0 | 0 | 0 | ||||||
| Oligodendroglioma grade III | 9 | 7 | 2 | 0 | 0 | 0 | ||||||
| Oligoastrocytoma grade III | 10 | 9 | 1 | 0 | 0 | 0 | ||||||
| Glioblastoma grade IV | 137 | 29 | 108 | 124 | 22 | 102 | ||||||
| IDH1/IDH2 WT | 116 | 0 | 116 | 101 | 0 | 101 | ||||||
| IDH1 MUT | 79 | 76 | 3‡ | 21 | 20 | 1 | ||||||
| IDH2 MUT | 3 | 3 | 0 | 2 | 2 | 0 | ||||||
| Tissue treated with RT/chemo | 14 | 11 | 3 | 0 | 0 | 0 | ||||||
| Tissue treated with isotretinoin | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Tissue received no treatment | 183 | 67 | 116 | 124 | 22 | 102 | ||||||
| Pretreatment data not available | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
* RBP1 methylation status was assessed by bisulfite sequencing in all 198 patients. If the average methylation level was greater than 50%, the sample was classified as methylated.
† The Total Cohort includes 41 patients from the initial screening cohort. Chemo = chemotherapy; IDH = isocitrate dehydrogenase; MUT = mutant; RBP1 = retinol binding protein 1; RT = radiotherapy; WT = wild type.
‡ All IDH1 MUT unmethylated patients had grade 4 gliomas.